BACTROBAN NASAL Rx
Generic Name and Formulations:
Mupirocin (as calcium) 2%; oint.
Indications for BACTROBAN NASAL:
Eradication of nasal colonization of methicillin-resistant S. aureus (MRSA) in adult patients and healthcare workers in certain institutional settings during outbreaks of infections with MRSA (see literature).
Apply approximately 0.25g to inside of each nostril twice daily for 5 days. Spread ointment by repeatedly closing and releasing the nostrils for 1 minute after application.
Avoid eyes. Nasal use in high-risk patients: see full labeling regarding autoinfection. Discontinue if sensitization or severe local irritation occurs. Prolonged use may result in superinfection. Pregnancy. Nursing mothers.
Nasal: avoid other concomitant nasal products.
Topical: burning, stinging, pain, itching. Nasal: headache, rhinitis, respiratory disorder, pharyngitis, taste perversion, burning/stinging, cough, pruritus; severe allergic reactions, C. difficile-associated diarrhea.
Oint—22g; Crm—15g, 30g; Nasal (single-use) (1g)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer